Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1,

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: <u>www.sunpharma.com</u> <u>Email: secretarial@sunpharma.com</u> CIN: L24230GJ1993PLC019050



June 27, 2024

National Stock Exchange of India Limited Scrip Symbol: SUNPHARMA BSE Limited Scrip Code: 524715

Subject - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory Order

This is to inform that the Company has received an order passed by statutory authority. Relevant details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in **Annexure A**.

The Company shall take appropriate action in the matter.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande) **Company Secretary and Compliance Officer** ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: <u>www.sunpharma.com</u> <u>Email: secretarial@sunpharma.com</u> CIN: L24230GJ1993PLC019050



Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
a)	Name of the authority	Jt. Commissioner, CGST and Central Excise, Mumbai.
b)	Nature and details of the action(s) taken, initiated or order(s) passed	Penalty of Rs.39,35,52,263 on the tax demanded.
c)	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	June 26, 2024
d)	Details of the violation(s)/ contravention(s) Committed or alleged to be committed	GST demand on settlement of damages with various Plaintiffs.
e)	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no immediate financial impact under this order as the Company is in the process of filing an appeal against this order.